Literature DB >> 23280786

Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system.

Enea Spada1, Alfonso Mele, Andrea Mariano, Ornella Zuccaro, Maria Elena Tosti.   

Abstract

Surveillance systems for acute hepatitis C allow monitoring of disease incidence trends and transmission patterns. This study aimed to describe the epidemiological profile of reported cases of symptomatic acute hepatitis C in Italy after the achievement of blood supply safety. The incidence of symptomatic acute hepatitis C since 1991 was estimated. Risk factors for acute hepatitis C were analyzed for the period 2003-2010 through a case-control study within a population-based surveillance for acute viral hepatitis. From 1991 to 2010, the incidence decreased from 2 to 0.2 per 100,000, with a more evident decrease among persons aged 15-24 years. During 2003-2010, 1,053 cases were reported. Intravenous drug use (adjusted odds ratio [(adj) OR], 30.5; 95% confidence interval [CI], 18.9-49.1), cohabitation or sexual partnership with an hepatitis C virus (HCV) carrier ((adj) OR, 11.2; 95% CI, 6.6-19.2), nosocomial exposure ((adj) OR, 6.6; 95% CI, 4.6-9.4); unsafe sexual practices ((adj) OR, 3.1; 95% CI, 1.9-5.2), and cosmetic treatments with percutaneous exposure ((adj) OR, 1.7; 95% CI, 1.2-2.4) were independently associated with acute hepatitis C. Population attributable risk estimates indicated nosocomial exposure (39.6%) and intravenous drug use (30.5%) as responsible for most cases. In conclusion, the incidence of symptomatic acute hepatitis C is declining in Italy. Currently, the most important risk factors are: having an HCV-positive household or sexual partner, unsafe sexual practices, cosmetic percutaneous treatments, intravenous drug use, and nosocomial exposure; the latter two factors are responsible for most cases. Effective prevention programs for intravenous drug users and strict adherence to universal precautions in healthcare settings are needed.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23280786     DOI: 10.1002/jmv.23485

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

Review 1.  Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.

Authors:  E Sagnelli; T Santantonio; N Coppola; M Fasano; M Pisaturo; C Sagnelli
Journal:  Infection       Date:  2014-03-12       Impact factor: 3.553

2.  Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.

Authors:  Enea Spada; Giovanni Rezza; Anna Rosa Garbuglia; Flavia Lucia Lombardo; Ornella Zuccaro; Francesca Menniti Ippolito; Elisabetta Cupellaro; Stefania Capone; Maria Rosaria Capobianchi; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Alfonso Mele
Journal:  J Urban Health       Date:  2018-02       Impact factor: 3.671

Review 3.  Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases.

Authors:  Giovanni B Gaeta; Massimo Puoti; Nicola Coppola; Teresa Santantonio; Raffaele Bruno; Antonio Chirianni; Massimo Galli
Journal:  Infection       Date:  2017-12-13       Impact factor: 3.553

4.  Hepatitis C virus and human immunodeficiency virus transmission routes: Differences and similarities.

Authors:  Francesca Cainelli
Journal:  World J Hepatol       Date:  2013-05-27

Review 5.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

6.  Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C.

Authors:  Enea Spada; Pietro Amoroso; Gloria Taliani; Ornella Zuccaro; Piergiorgio Chiriacò; Patrizia Maio; Giuseppe Maio; Maria Luisa Esposito; Corrado Mariano; Roberto Rinaldi; Pietro Bellissima; Maria Elena Tosti; Paola Del Porto; Ruggiero Francavilla; Vincenzo Mellace; Anna Rosa Garbuglia; Antonella Folgori; Alfonso Mele
Journal:  Clin Infect Dis       Date:  2013-06-19       Impact factor: 9.079

7.  Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.

Authors:  Loreta A Kondili; Lucia Craxì; Massimo Andreoni; Francesco S Mennini; Homie Razavi
Journal:  Liver Int       Date:  2022-05       Impact factor: 8.754

8.  Distinct features in natural history and outcomes of acute hepatitis C.

Authors:  Chalermrat Bunchorntavakul; Lisa M Jones; Masahiro Kikuchi; Mary E Valiga; David E Kaplan; Frederick A Nunes; Ayse Aytaman; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Clin Gastroenterol       Date:  2015-04       Impact factor: 3.062

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.